Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jun 1;35(6):488–497. doi: 10.1089/jir.2014.0209

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2015, Mary Ann Liebert, Inc.

PMC Copyright notice

FIG. 4. — STAT1 phosphorylation and ISG promoter activity is desensitized as a result of IFN-α pretreatment, and resensitized with the addition of PPARα agonist WY-14643. JFH1-infected cells were treated with 2 U/mL IFN-α for 3 weeks, alone or in combination with WY-14643, or mock treated, then treated with 20 U/mL IFN-α. Following the addition of 20 U/mL IFN-α, STAT1 and pSTAT1 western blots were performed (A), and ISRE/GAS promoter activation was examined using luciferase reporter plasmids (B). Pretreatment with IFN-α significantly reduced STAT1 phosphorylation following subsequent IFN-α treatment, which was partially restored with concurrent WY-14643 pretreatment (3 experimental replicates performed in duplicate). IFN-α pretreatment also significantly decreased sensitivity of ISRE activation at 8 and 24 h post-IFN-α treatment. Pretreatment with WY-14643 rescued ISRE sensitivity to levels similar to untreated cells. There was a trend toward reduced GAS activation in cells treated with both WY-14643 and IFN-α, compared with IFN-α alone. *Significant difference between treatment and control, and significant difference between IFN and IFN plus WY-14643 treatment. Graphs demonstrate an average of 3 experimental replicates (P<0.05, P<0.01). pSTAT1, phosphorylation of STAT1.

Inline graphic — STAT1 phosphorylation and ISG promoter activity is desensitized as a result of IFN-α pretreatment, and resensitized with the addition of PPARα agonist WY-14643. JFH1-infected cells were treated with 2 U/mL IFN-α for 3 weeks, alone or in combination with WY-14643, or mock treated, then treated with 20 U/mL IFN-α. Following the addition of 20 U/mL IFN-α, STAT1 and pSTAT1 western blots were performed (A), and ISRE/GAS promoter activation was examined using luciferase reporter plasmids (B). Pretreatment with IFN-α significantly reduced STAT1 phosphorylation following subsequent IFN-α treatment, which was partially restored with concurrent WY-14643 pretreatment (3 experimental replicates performed in duplicate). IFN-α pretreatment also significantly decreased sensitivity of ISRE activation at 8 and 24 h post-IFN-α treatment. Pretreatment with WY-14643 rescued ISRE sensitivity to levels similar to untreated cells. There was a trend toward reduced GAS activation in cells treated with both WY-14643 and IFN-α, compared with IFN-α alone. *Significant difference between treatment and control, and significant difference between IFN and IFN plus WY-14643 treatment. Graphs demonstrate an average of 3 experimental replicates (P<0.05, P<0.01). pSTAT1, phosphorylation of STAT1.